Inge Marie Svane

Inge Marie Svane

Clinical Professor

Member of:

  • Clinical Oncology

ORCID: 0000-0002-9451-6037

Publication year:
All
11 - 20 out of 27Page size: 10
  1. 2022
  2. Published

    Coexisting Alterations of MHC Class I Antigen Presentation and IFNg Signaling Mediate Acquired Resistance of Melanoma to Post-PD-1 Immunotherapy

    Nielsen, M., Presti, M., Sztupinszki, Z., Jensen, Agnete Witness Præst, Draghi, A., Chamberlain, C. A., Schina, A., Yde, C. W., Wojcik, J., Szallasi, Z., Crowther, M. D., Svane, Inge Marie & Donia, M., 2022, In: Cancer Immunology Research. 10, 10, p. 1254-1262 9 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  3. Published

    Epigenetic therapy in combination with a multi-epitope cancer vaccine targeting shared tumor antigens for high-risk myelodysplastic syndrome - a phase I clinical trial

    Holmberg-Thydén, S., Dufva, I. H., Gang, Anne Ortved, Breinholt, M. F., Schejbel, L., Andersen, M. K., Kadivar, M., Svane, Inge Marie, Grønbæk, Kirsten, Hadrup, S. R. & El Fassi, D., 2022, In: Cancer Immunology, Immunotherapy. 71, p. 433-444

    Research output: Contribution to journal › Journal article › Research › peer-review

  4. Published

    Feasibility of Intratumoral Anti-PD1 as Treatment of Human Basal Cell Carcinoma: An Explorative Study with Adjuvant Ablative Fractional Laser

    Omland, S. H., Ejlertsen, J. S., Krustrup, D., Christensen, R. L., Svane, Inge Marie, Olesen, U. H. & Hædersdal, Merete, 2022, In: Cancers. 14, 23, 5815.

    Research output: Contribution to journal › Journal article › Research › peer-review

  5. Published

    Fibrotic activity quantified in serum by measurements of type III collagen pro-peptides can be used for prognosis across different solid tumor types

    Willumsen, N., Jensen, C., Green, G., Nissen, N. I., Neely, J., Nelson, D. M., Pedersen, R. S., Frederiksen, P., Chen, I. M., Boisen, M. K., Johansen, A. Z., Madsen, D. H., Svane, I. M., Lipton, A., Leitzel, K., Ali, S. M., Erler, J. T., Hurkmans, D. P., Mathijssen, R. H. J., Aerts, J. & 5 others, Eslam, M., George, J., Christiansen, C., Bissel, M. J. & Karsdal, M. A., 2022, In: Cellular and Molecular Life Sciences. 79, 4, 11 p., 204.

    Research output: Contribution to journal › Review › Research › peer-review

  6. Published

    Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy

    Chamberlain, C. A., Bennett, Eric Paul, Kverneland, Anders Handrup, Svane, Inge Marie, dqp123, dqp123 & Met, Özcan, 2022, In: Molecular Therapy - Oncolytics. 24, p. 417-428 12 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  7. Published

    Hud, blod og lymfesystem

    Hendel, Helle Westergren, Chakera, A. H., Svane, Inge Marie, Pedersen, Lars Møller, Oturai, P. S., Jensen, M. R. & Glenthøj, Andreas Birkedal, 2022, Klinisk Nuklearmedicin. Munksgaard , p. 187-220

    Research output: Chapter in Book/Report/Conference proceeding › Book chapter › Communication

  8. Published

    Manufacture of adoptive cell therapies at academic cancer centers: scientific, safety and regulatory challenges

    Saini, K. S., Svane, Inge Marie, Juan, M., Barlesi, F. & André, F., 2022, In: Annals of Oncology. 33, 1, p. 6-12 7 p.

    Research output: Contribution to journal › Editorial › Research › peer-review

  9. Published

    Neoantigen-reactive CD8+ T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanoma

    Kristensen, N. P., Heeke, C., Tvingsholm, S. A., Borch, A., Draghi, A., Crowther, M. D., Carri, I., Munk, K. K., Holm, J. S., Bjerregaard, A. M., Bentzen, A. K., Marquard, A. M., Szallasi, Z., McGranahan, N., Andersen, R., Nielsen, M., Jönsson, G. B., dqp123, dqp123, Svane, Inge Marie & Hadrup, S. R., 2022, In: Journal of Clinical Investigation. 132, 2, p. 1-16 150535.

    Research output: Contribution to journal › Journal article › Research › peer-review

  10. Published

    Peptide vaccination activating Galectin-3-specific T cells offers a novel means to target Galectin-3-expressing cells in the tumor microenvironment

    Bendtsen, S. K., Perez Penco, Maria, Hübbe, M. L., Martinenaite, E., Orebo Holmström, M., Weis-Banke, S. E., Grønne Dahlager Jørgensen, N., Jørgensen, M. A., Munir Ahmad, S., Jensen, K. M., Friese, C., Lundsager, M. T., Johansen, A. Z., Carretta, M., Ødum, Niels, Met, Özcan, Svane, Inge Marie, Madsen, Daniel Hargbøl & Andersen, Mads Hald, 2022, In: OncoImmunology. 11, 1, 2026020.

    Research output: Contribution to journal › Journal article › Research › peer-review

  11. Published

    Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st–2nd, 2021

    Ascierto, P. A., Avallone, A., Bhardwaj, N., Bifulco, C., Bracarda, S., Brody, J. D., Buonaguro, L., Demaria, S., Emens, L. A., Ferris, R. L., Galon, J., Khleif, S. N., Klebanoff, C. A., Laskowski, T., Melero, I., Paulos, C. M., Pignata, S., Ruella, M., Svane, I. M., Taube, J. M. & 3 others, Fox, B. A., Hwu, P. & Puzanov, I., 2022, In: Journal of Translational Medicine. 20, 1, 257.

    Research output: Contribution to journal › Journal article › Research › peer-review

Previous 1 2 3 Next

ID: 4054758